LSTA – lisata therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors [Yahoo! Finance]
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma [Yahoo! Finance]
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma [Yahoo! Finance]
Form S-3 LISATA THERAPEUTICS,
Form DEFA14A LISATA THERAPEUTICS,
Form DEF 14A LISATA THERAPEUTICS, For: Apr 29
Form 3 LISATA THERAPEUTICS, For: Apr 15 Filed by: Nisco James
Form 8-K LISATA THERAPEUTICS, For: Apr 15
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.